Passionflower for Opioid Withdrawal

Verdict: Weak, unproven; risky alongside opioids

Evidence that passionflower (Passiflora incarnata) helps with opioid withdrawal is weak and rests on a single small, dated trial where it was only added to clonidine. It should not replace standard medical treatment, and combining it with opioids or other sedatives may dangerously deepen drowsiness and slow breathing.

C 🟠 C Weak Evidence Safety Review

🔬Why this grade7-layer evidence engine

The grade is Weak Evidence because the only direct human data is one double-blind RCT from 2001 (PMID 11679027, n=65, 14 days). Crucially, passionflower was used as an add-on to clonidine, not on its own: it matched clonidine alone for physical withdrawal symptoms and beat it only for mental/psychological symptoms. The trial is single-center, over two decades old, has not been replicated, and its funding was not disclosed.

A 2021 systematic review of integrative medicine for opioid withdrawal (PMID 34016305) included passionflower among seven interventions but did not isolate its effect, and judged the overall evidence base limited by small samples. No firm, passionflower-specific efficacy conclusion exists.

Regulators and clinics offer no support for this use. The US FDA lists passionflower only as a food/flavoring substance, not a treatment, and major bodies (NIH ODS, Mayo Clinic, Cleveland Clinic, Harvard Health, WHO) do not address it for withdrawal. The Safety Review flag reflects a real interaction risk: passionflower can add to the sedation and respiratory depression of opioids and other CNS depressants. Opioid withdrawal is a serious condition best managed with proven therapies such as buprenorphine, methadone, or FDA-approved lofexidine/clonidine.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.54
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Safety Review
Confidence
68%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.535
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial
PMID: 11679027 2001 RCT (double-blind) n = 65
Finding: Both groups equally effective for physical withdrawal symptoms; passiflora+clonidine showed significant superiority over clonidine alone for mental symptoms (p-value not reported in abstract).
View on PubMed
A systematic review of integrative medicine for opioid withdrawal
PMID: 34016305 2021 系統性回顧
Finding: 7 studies reviewed; most supported integrative medicine for OWS but evidence strength limited by small samples; no separate efficacy conclusion for passionflower.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Neutral
PASSION FLOWER (PASSIFLORA INCARNATA L.) source↗
L4b EU EFSA
Neutral
L4d TW TFDA / 衛福部
Cautious
未經確認其食用安全性前,不得供為食品原料使用。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-opioid-withdrawal-INT-passionflower-001 繁體中文版 →